Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
-
ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
-
Austin, TX, USA, May 19, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Cholera Vaccine Market Size, Trends and Insights By Type (Whole Cell v. Cholerae...
-
Pharming today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS) in New Orleans, LA.
-
Lighthouse Autism Center is Opening in Rocky Mount, North Carolina in June 2026
-
MINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces...
-
Micron Biomedical makes the Most Innovative Companies List in recognition of clinical, financial and other progress toward needle-free vaccines and drugs.
-
Lighthouse Autism Center is Opening in Asheboro, North Carolina this August
-
BOOST Pharma appoints revered biopharma leader Elaine Jones as Chair, strengthening leadership as BT‑101 advances toward late‑stage development for OI.
-
Standard Process launches SP Children’s ProSynbiotic, a whole food-based synbiotic designed to support digestive regularity, gut balance and immune health.